GlobeNewsWire
03 Jun 2026, 02:47 UTC · 3h ago
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
Search tags
GlobeNewsWire
03 Jun 2026, 02:47 UTC · 3h ago
Search tags
Story key points
4 claims · impact-rated
InnoCare Pharma's BCL2 inhibitor mesutoclax showed a 100% overall response rate (ORR) in treatment-naïve MDS patients. — Extremely high efficacy rates in a clinical trial for cancer treatment typically drive significant positive valuation for biotech firms.
+0.80Mesutoclax achieved a composite complete response (cCR) rate of 81.8% and a 0% mortality rate at 30 and 60 days in treatment-naïve AML patients. — Strong efficacy paired with a high safety profile (low mortality) reduces clinical trial risk and increases the probability of regulatory approval.
+0.70The mesutoclax regimen demonstrated a 71.4% cCR rate specifically in TN AML patients with TP53 mutations, a historically difficult-to-treat group. — Success in high-unmet-need subpopulations expands the potential addressable market and competitive advantage.
+0.60Continue reading
6 related stories
Clinical data for mesutoclax showed no dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) was not reached. — A wide safety window suggests a favorable benefit-risk profile, which is critical for FDA/NMPA approval processes.
+0.50Ticker attribution
Model heads
The company reported outstanding efficacy and safety data for its novel BCL2 inhibitor mesutoclax in MDS and AML.
The company reported outstanding efficacy and safety data for its novel BCL2 inhibitor mesutoclax in MDS and AML.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
5 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
GlobeNewsWire
20h ago
